Single-agent immunotherapy was a good start. Anti-PD-1 alone delivers durable responses in melanoma, lung cancer, and a handful of other tumor types. But for most cancers, monotherapy response rates hover in the 15-25% range, which means the majority of patients get the side effects without the benefit. The field's answer: combine everything with everything and see what works. It sounds chaotic because it sort of is.
Why One Drug Is Not Enough
The immune system's relationship with cancer is not a single broken wire you can fix with one tool. It is more like a house where someone has simultaneously cut the power, changed the locks, hired fake security, and filled the hallways with fog. Checkpoint inhibitors address one problem - they remove the "do not attack" signal that tumors exploit. But if T cells cannot find the tumor, are not properly activated, or get exhausted before they finish the job, removing one brake is not enough.
This is the biological rationale for combinations. Different drugs address different parts of the immune failure.
The Combinations That Work
Anti-PD-1 + Anti-CTLA-4. The OG combo. Nivolumab plus ipilimumab (CheckMate trials) showed that blocking two different checkpoints simultaneously produces deeper, more durable responses than either alone. CTLA-4 blockade primarily boosts T cell activation in lymph nodes, while PD-1 blockade unleashes T cells at the tumor site. Together, you get more T cells that are more aggressive. The trade-off: significantly higher toxicity rates, including serious autoimmune complications. This combo is approved for melanoma, renal cell carcinoma, hepatocellular carcinoma, NSCLC, and mesothelioma.
Checkpoint inhibitor + chemotherapy. Counterintuitive - chemo kills immune cells, so why pair it with immunotherapy? Turns out chemo causes immunogenic cell death (releasing tumor antigens), reduces immunosuppressive cell populations, and creates space for fresh immune cells. Pembrolizumab plus chemo is now first-line for NSCLC, and similar combos are standard in gastric, esophageal, and triple-negative breast cancer.
Checkpoint inhibitor + anti-angiogenic. Bevacizumab plus atezolizumab in hepatocellular carcinoma (IMbrave150) was a landmark - the first regimen to beat sorafenib as first-line therapy for liver cancer in over a decade. Anti-angiogenics normalize tumor vasculature, improving T cell infiltration, and reduce VEGF-mediated immune suppression. The pairing makes biological sense and the clinical data backs it up.
Checkpoint inhibitor + targeted therapy. In melanoma, combining immunotherapy with BRAF/MEK inhibitors is being sequenced and combined in various configurations. In renal cell carcinoma, pembrolizumab plus lenvatinib or axitinib has become standard of care. The targeted drug shrinks the tumor and modulates the microenvironment while the checkpoint inhibitor maintains long-term immune control.
The Combinations Being Tested
The frontier gets wilder. LAG-3 inhibitors (relatlimab, already approved with nivolumab for melanoma), TIGIT inhibitors, bispecific antibodies, oncolytic viruses, STING agonists, TLR agonists, cancer vaccines, CAR-T cells, fecal microbiota transplantation - all are being combined with checkpoint inhibitors in various permutations.
The number of active combination immunotherapy trials exceeded 5,000 as of 2025. Five thousand. Each one testing a slightly different cocktail in a slightly different patient population. Keeping track of which combos work, which ones add toxicity without benefit, and which ones are redundant is a genuine information management problem.
The Toxicity Tax
More drugs means more side effects. Combination immunotherapy regimens carry higher rates of immune-related adverse events - colitis, hepatitis, pneumonitis, endocrinopathies, and occasionally life-threatening complications. The anti-PD-1/anti-CTLA-4 combination produces grade 3-4 adverse events in roughly 55-60% of patients, compared to about 20% with anti-PD-1 alone.
This is not a minor footnote. Toxicity management has become a subspecialty within oncology. Knowing when to hold treatment, when to give steroids, and when a rash is just a rash versus the start of something serious requires experience and vigilance.
The Rational Design Problem
Most current combinations were discovered empirically - try it and see - rather than designed from first principles. Biomarker-driven patient selection remains the missing piece. PD-L1, tumor mutational burden, microsatellite instability, gene expression signatures - all provide some predictive value, but none is sufficient alone. The patient who responds spectacularly and the one who gets hospitalized with colitis may look identical on paper.
For anyone tracking the sheer volume of combination trial data, mapb2.io can help organize which combos are being tested against which tumor types - before your browser tab count hits triple digits.
The era of monotherapy immunotherapy is effectively over for most cancers. The era of rational combinations is beginning, and it is messy, expensive, and promising in roughly equal measure.
References
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127-137. DOI: 10.1200/JCO.21.02229 | PMID: 34818112
- Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905. DOI: 10.1056/NEJMoa1915745 | PMID: 32402160
Disclaimer: This blog post is for informational and educational purposes only. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions.
Get cancer research delivered to your inbox
The best new studies, explained without the jargon. One email per week.